Vanguard Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,834,519
| Closed | -$36.8M | – | 4346 |
|
|
2024
Q4 | $36.8M | Buy |
3,834,519
+171,063
| +5% | +$893K | ﹤0.01% | 2291 |
|
|
2024
Q3 | $10.5M | Buy |
3,663,456
+257,651
| +8% | +$798K | ﹤0.01% | 2931 |
|
|
2024
Q2 | $9.9M | Buy |
3,405,805
+32,740
| +1% | +$89.5K | ﹤0.01% | 2929 |
|
|
2024
Q1 | $10.8M | Buy |
3,373,065
+473,746
| +16% | +$1.58M | ﹤0.01% | 2924 |
|
|
2023
Q4 | $9.7M | Buy |
2,899,319
+260,865
| +10% | +$672K | ﹤0.01% | 2963 |
|
|
2023
Q3 | $6.28M | Buy |
2,638,454
+47,255
| +2% | +$99K | ﹤0.01% | 3155 |
|
|
2023
Q2 | $4.56M | Buy |
2,591,199
+230,447
| +10% | +$589K | ﹤0.01% | 3350 |
|
|
2023
Q1 | $7.27M | Buy |
2,360,752
+29,446
| +1% | +$176K | ﹤0.01% | 3124 |
|
|
2022
Q4 | $12.4M | Sell |
2,331,306
-53,560
| -2% | -$245K | ﹤0.01% | 2855 |
|
|
2022
Q3 | $8.42M | Buy |
2,384,866
+1,059,216
| +80% | +$3.5M | ﹤0.01% | 3045 |
|
|
2022
Q2 | $3.42M | Sell |
1,325,650
-120,614
| -8% | -$335K | ﹤0.01% | 3561 |
|
|
2022
Q1 | $6.48M | Sell |
1,446,264
-5,891
| -0.4% | -$26.6K | ﹤0.01% | 3391 |
|
|
2021
Q4 | $9.9M | Sell |
1,452,155
-63,039
| -4% | -$429K | ﹤0.01% | 3209 |
|
|
2021
Q3 | $11M | Buy |
1,515,194
+184,743
| +14% | +$1.59M | ﹤0.01% | 3180 |
|
|
2021
Q2 | $13.3M | Sell |
1,330,451
-106,883
| -7% | -$957K | ﹤0.01% | 3055 |
|
|
2021
Q1 | $13.7M | Buy |
1,437,334
+849,245
| +144% | +$8.33M | ﹤0.01% | 2982 |
|
|
2020
Q4 | $6.45M | Buy |
588,089
+21,138
| +4% | +$223K | ﹤0.01% | 3224 |
|
|
2020
Q3 | $5.03M | Buy |
+566,951
| New | +$6.45M | ﹤0.01% | 3138 |
|
Other funds holding PSTX
Vanguard Group's PSTX Position: Q1 2025 in Review
Vanguard Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 3,834,519 shares — an estimated $36.8M sold.
Vanguard Group first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $36.8M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Vanguard Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Vanguard Group sold 3,834,519 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $36.8M.
- Vanguard Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Vanguard Group's Poseida Therapeutics, Inc. Common Stock position peaked at $36.8M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.